Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1978 Aug;62(2):496–499. doi: 10.1172/JCI109152

Factor VIII/von Willebrand factor protein. Galactose a cryptic determinant of von Willebrand factor activity.

H R Gralnick
PMCID: PMC371789  PMID: 307560

Abstract

The normal Factor VIII/von Willebrand factor protein has the ability to agglutinate or aggregate normal platelets in the presence of ristocetin (von Willebrand factor activity). Removal of greater than 95% of the sialic acid from this protein by neuraminidase did not affect the von Willebrand factor or procoagulant activity. However, oxidation of the penultimate galactose of the asialo Factor VIII/von Willebrand factor protein with galactose oxidase resulted in a progressive loss of von Willebrand factor activity with no effect on procoagulant activity. Reduction of the 6-aldehydo intermediate by potassium borohydride caused full regeneration of von Willebrand factor activity. These studies confirm the identification of the intact penultimate galactose moiety as a critical determinant of von Willebrand factor activity.

Full text

PDF
496

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bouma B. N., Wiegerinck Y., Sixma J. J., Van Mourik J. A., Mochtar I. A. Immunological characterization of purified anti-haemophilic factor A (factor VIII) which corrects abnormal platelet retention in Von Willebrand's disease. Nat New Biol. 1972 Mar 29;236(65):104–106. doi: 10.1038/newbio236104a0. [DOI] [PubMed] [Google Scholar]
  2. Coller B. S., Franza B. R., Jr, Gralnick H. R. The pH dependence of quantitative ristocetin-induced platelet aggregation: theoretical and practical implications-a new device for maintenance of platelet-rich plasma pH. Blood. 1976 May;47(5):841–854. [PubMed] [Google Scholar]
  3. Cuatrecasas P., Illiano G. Purification of neuraminidases from Vibrio Cholerae, Clostridium Perfringens and influenza virus by affinity chromatography. Biochem Biophys Res Commun. 1971 Jul 2;44(1):178–184. doi: 10.1016/s0006-291x(71)80175-4. [DOI] [PubMed] [Google Scholar]
  4. Gralnick H. R., Coller B. S. Studies of the human factor VIII/von Willebrand's factor protein. II. Identification and characterization of the von Willebrand protein. Blood. 1975 Sep;46(3):417–430. [PubMed] [Google Scholar]
  5. Gralnick H. R., Coller B. S., Sultan Y. Carbohydrate deficiency of the factor VIII/von Willebrand factor Protein in von Willebrand's disease variants. Science. 1976 Apr 2;192(4234):56–59. doi: 10.1126/science.1083071. [DOI] [PubMed] [Google Scholar]
  6. Gralnick H. R., Coller B. S., Sultan Y. Studies of the human factor VIII/von Willebrand factor protein. III. Qualitative defects in von Willebrand's disease. J Clin Invest. 1975 Oct;56(4):814–827. doi: 10.1172/JCI108160. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Gralnick H. R., Sultan Y., Coller B. S. Von Willebrand's disease: combined qualitative and quantitative abnormalities. N Engl J Med. 1977 May 5;296(18):1024–1030. doi: 10.1056/NEJM197705052961802. [DOI] [PubMed] [Google Scholar]
  8. Kirby E. P. Factor VIII-associated platelet aggregation. Thromb Haemost. 1977 Dec 15;38(4):1054–1072. [PubMed] [Google Scholar]
  9. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  10. Legaz M. E., Schmer G., Counts R. B., Davie E. W. Isolation and characterization of human Factor VIII (antihemophilic factor). J Biol Chem. 1973 Jun 10;248(11):3946–3955. [PubMed] [Google Scholar]
  11. Levy-Toledano S., Caen J. P., Halmos T., Mester L. Dissociation between human platelet agglomerating activity and factor VIII procoagulant activity of bovine plasma preparations by chemical treatment. I. Effect of neuraminidase. Pathol Biol (Paris) 1973 Nov;21(Suppl):60–62. [PubMed] [Google Scholar]
  12. Marchesi S. L., Shulman N. R., Gralnick H. R. Studies on the purification and characterization of human factor 8. J Clin Invest. 1972 Aug;51(8):2151–2161. doi: 10.1172/JCI107022. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Peake I. R., Bloom A. L. Abnormal factor VIII related antigen (FVIIIRAG) in von Willebrand's disease (vWd): decreased precipitation by concanavalin A. Thromb Haemost. 1977 Apr 30;37(2):361–362. [PubMed] [Google Scholar]
  14. Sodetz J. M., Pizzo S. V., McKee P. A. Relationship of sialic acid to function and in vivo survival of human factor VIII/von Willebrand factor protein. J Biol Chem. 1977 Aug 10;252(15):5538–5546. [PubMed] [Google Scholar]
  15. WARREN L. The thiobarbituric acid assay of sialic acids. J Biol Chem. 1959 Aug;234(8):1971–1975. [PubMed] [Google Scholar]
  16. Weiss H. J., Rogers J., Brand H. Defective ristocetin-induced platelet aggregation in von Willebrand's disease and its correction by factor VIII. J Clin Invest. 1973 Nov;52(11):2697–2707. doi: 10.1172/JCI107464. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Williams H. R., Lin T. Y. Methyl- 14 C-glycinated hemoglobin as a substrate for proteases. Biochim Biophys Acta. 1971 Dec 15;250(3):603–607. doi: 10.1016/0005-2744(71)90265-8. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES